Well done to Invex on hitting another milestone. Another tick and demonstrates an extremely competent management team.
The lack of volume reflects an uninterested market awaiting the outcome of negotiating with the FDA about one vs. two trials.
Still waiting with bated breath for the formulation and CMO appointment but it appears it’s probably delayed in the setting of COVID.
Ann: Invex Files Pre-IND/Type B Meeting Request with US FDA, page-4
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
